Barclays’s VanEck Pharmaceutical ETF PPH Stock Holding History

Barclays’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-32,000	Closed	-$2.89M	–	5581
2025 Q3	$2.89M	Buy	+32,000	New	+$2.8M	﹤0.01%	2594

Other funds holding PPH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

JSAM

J. Safra Asset Management New York $2.17B AUM 29.66% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Avalon Trust Santa Fe, New Mexico $1.63B AUM 42.75% 1-Year Est. Return

AWC

Adamsbrown Wealth Consultants Wichita, Kansas $530M AUM 23.21% 1-Year Est. Return

Barclays's PPH Position: Q2 2026 in Review

Barclays sold out of VanEck Pharmaceutical ETF (PPH) in Q2 2026, closing a stake of 457 shares — an estimated $47.5K sold.

Barclays first reported a position in PPH in Q3 2014 and held it in 18 quarters. The position peaked at $15.8M in Q3 2014. 148 funds tracked by Wall St. Rank hold PPH as of Q2 2026.

Barclays reported no remaining VanEck Pharmaceutical ETF position as of Q2 2026 after selling out during the quarter.
Barclays sold 457 VanEck Pharmaceutical ETF shares in Q2 2026, an estimated $47.5K.
Barclays first reported a position in VanEck Pharmaceutical ETF in Q3 2014 and held it in 18 quarters.
Barclays's VanEck Pharmaceutical ETF position peaked at $15.8M in Q3 2014.
148 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.